New brachy product begins use

Article

The first patient has been treated with the Flexitron brachytherapy product, available from Nucletron and its developer, Isodose Control.

New brachy product begins use
The first patient has been treated with the Flexitron brachytherapy product, available from Nucletron and its developer, Isodose Control. The 40-channel afterloader was applied in the treatment of breast cancer at the Cancer Specialists of Oklahoma in Oklahoma City. Flexitron was recently integrated into Nucletron's offering of high dose rate brachytherapy afterloaders, applicators, and treatment planning solutions Sept. 1 when Nucletron and Isodose Control forged a partnership to serve the global brachytherapy marketplace. Nucletron is framing the newly introduced product as the next generation of afterloading platforms for cancer treatment. The brachytherapy product employs a 40-channel radiation delivery system with DICOM compatibility and includes dual radiation source capabilities and multiple isotope compatibility.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.